Please ensure Javascript is enabled for purposes of website accessibility

Does Gilead Have a Cure for the Coronavirus?

By Adria Cimino – Jun 21, 2020 at 8:00AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Gilead’s remdesivir is helping many COVID-19 patients recover, and trials continue to maximize its potential.

Gilead Sciences (GILD -0.83%) is among many biotech and pharmaceutical companies working on treatments for COVID-19, the illness caused by the novel coronavirus. Where Gilead stands apart is it actually has a treatment that the U.S. Food and Drug Administration (FDA) has authorized for emergency use.

What is remdesivir?

Gilead initially developed remdesivir as part of its hepatitis C and respiratory syncytial virus (RSV) research in 2009. With the Ebola outbreak a few years later, the company explored the antiviral's potential, but other treatments produced better survival rates. Preclinical data in other coronaviruses, severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), were promising, but clinical trials couldn't be conducted because it couldn't enroll enough patients as cases declined. Maintaining a strong belief in remdesivir's potential, Gilead renewed preclinical studies of the drug once COVID-19 emerged.

As a nucleoside analog, remdesivir "pretends" to be a nucleoside that occurs naturally in the virus. But instead of helping the virus replicate, this imposter interrupts the process. The drug is administered intravenously over a period of five to 10 days.

Coronavirus triage bay

Image source: Getty Images.

Does remdesivir cure COVID-19?

Remdesivir doesn't cure COVID-19, but a National Institute of Allergy and Infectious Diseases trial demonstrated the drug's ability to help patients recover faster.

Gilead-sponsored trials added to the positive data. In a phase 3 trial, Gilead studied remdesivir in hospitalized patients with moderate COVID-19 pneumonia compared with a standard of care group. According to the latest results, patients given remdesivir for a period of five days were 65% more likely to show clinical improvement on the 11th day following the start of treatment than those given standard care.

In another phase 3 study, Gilead examined the use of remdesivir in hospitalized patients with severe COVID-19. That study showed that patients taking a five-day treatment experienced about the same benefit as those on a 10-day regimen. Fourteen days after the start of treatment, more than 64% of patients in the five-day group and nearly 54% in the 10-day group had achieved clinical recovery. "Clinical recovery" means the patient no longer needs medical treatment. The study also found that patients who received remdesivir within 10 days of the first symptoms had better outcomes than those given the treatment later.

Currently, there are more than 20 recruiting or active remdesivir trials worldwide, according to ClinicalTrials.gov. Gilead has said it is donating more than 1 million doses of remdesivir to U.S. hospitals and clinical trials.

Are other COVID-19 treatments in clinical trials?

Other companies and research teams are testing possible treatments for COVID-19 in clinical trials around the world. Partners Sanofi (SNY -3.00%) and Regeneron (REGN -1.61%) are exploring the use of rheumatoid arthritis drug Kevzara with the hope it may reduce the body's inflammatory response. So far, studies have shown a possible benefit to critical patients but no benefit to patients with severe COVID-19. Testing will continue in critical patients only.

Separately, Regeneron started a clinical trial this month on an antiviral antibody cocktail for the prevention and treatment of COVID-19. The study includes four groups: patients hospitalized with the virus, non-hospitalized COVID-19 patients, uninfected people in high-risk positions like healthcare, and uninfected people who have close contact with a COVID-19 patient (such as a family member).

Researchers also continue to study the anti-malaria drug hydroxychloroquine in more than 100 clinical trials worldwide, even after the FDA revoked the treatment's emergency use authorization and several studies indicated the drug wasn't efficacious. Hydroxychloroquine sparked controversy after President Trump touted its benefits. Some took the drug without the surveillance of a doctor, resulting in serious injury or death. That's why it is essential to speak with a doctor before taking any prescription medication.

There are more than 1,300 active or recruiting clinical trials worldwide investigating therapies for COVID-19, ClinicalTrials.gov data show. Treatments involved in testing include plasma-based therapy, traditional Chinese medicine, corticosteroids, and many others.

So far, remdesivir shows great promise in treating COVID-19 patients, but there is still much more research needed before it's deemed a cure.

Adria Cimino has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
GILD
$62.34 (-0.83%) $0.52
Sanofi Stock Quote
Sanofi
SNY
$37.25 (-3.00%) $-1.15
Regeneron Pharmaceuticals, Inc. Stock Quote
Regeneron Pharmaceuticals, Inc.
REGN
$686.10 (-1.61%) $-11.23

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
329%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.